Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $8.0 million.

  • SAB Biotherapeutics' Total Current Liabilities rose 22.43% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 22.43%. This contributed to the annual value of $8.0 million for FY2024, which is 26.21% down from last year.
  • As of FY2024, SAB Biotherapeutics' Total Current Liabilities stood at $8.0 million, which was down 26.21% from $10.8 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Total Current Liabilities high stood at $26.5 million for FY2021, and its period low was $8.0 million during FY2024.
  • Its 3-year average for Total Current Liabilities is $11.3 million, with a median of $10.8 million in 2023.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first spiked by 139.16% in 2021, then plummeted by 43.33% in 2022.
  • Over the past 5 years, SAB Biotherapeutics' Total Current Liabilities (Yearly) stood at $11.1 million in 2020, then soared by 139.16% to $26.5 million in 2021, then plummeted by 43.33% to $15.0 million in 2022, then declined by 27.88% to $10.8 million in 2023, then dropped by 26.21% to $8.0 million in 2024.